Running Oak Capital LLC Raises Position in IQVIA Holdings Inc. (NYSE:IQV)

Running Oak Capital LLC lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 20.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 38,475 shares of the medical research company’s stock after buying an additional 6,446 shares during the quarter. Running Oak Capital LLC’s holdings in IQVIA were worth $8,902,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of IQV. International Assets Investment Management LLC bought a new position in shares of IQVIA during the fourth quarter valued at approximately $13,759,000. Schwartz Investment Counsel Inc. lifted its position in IQVIA by 4.1% during the fourth quarter. Schwartz Investment Counsel Inc. now owns 178,690 shares of the medical research company’s stock valued at $41,345,000 after acquiring an additional 7,050 shares during the last quarter. Gilliland Jeter Wealth Management LLC purchased a new stake in IQVIA during the fourth quarter valued at approximately $986,000. Dfpg Investments LLC purchased a new stake in IQVIA during the fourth quarter valued at approximately $1,106,000. Finally, Sei Investments Co. lifted its position in IQVIA by 20.2% during the third quarter. Sei Investments Co. now owns 94,748 shares of the medical research company’s stock valued at $18,641,000 after acquiring an additional 15,913 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other news, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the sale, the insider now owns 5,251 shares in the company, valued at $1,313,642.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the transaction, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the sale, the insider now owns 20,836 shares in the company, valued at $5,031,894. The disclosure for this sale can be found here. Insiders have sold a total of 41,285 shares of company stock worth $10,331,003 in the last three months. Company insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

IQV has been the subject of a number of research analyst reports. BTIG Research initiated coverage on shares of IQVIA in a report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price target for the company. Robert W. Baird raised their target price on shares of IQVIA from $226.00 to $251.00 and gave the stock a “neutral” rating in a report on Thursday, February 15th. Guggenheim cut shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Evercore ISI raised their target price on shares of IQVIA from $255.00 to $265.00 and gave the stock a “market outperform” rating in a report on Thursday, February 15th. Finally, StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $259.43.

IQVIA Price Performance

Shares of IQV traded down $10.80 during trading hours on Thursday, reaching $222.14. The company had a trading volume of 1,697,675 shares, compared to its average volume of 973,070. The firm has a 50 day simple moving average of $245.07 and a 200-day simple moving average of $223.85. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. The company has a market capitalization of $40.32 billion, a price-to-earnings ratio of 31.95, a PEG ratio of 2.24 and a beta of 1.52. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, beating analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The firm had revenue of $3.87 billion for the quarter, compared to analysts’ expectations of $3.80 billion. During the same period in the prior year, the company earned $2.54 EPS. The firm’s revenue was up 3.5% on a year-over-year basis. Research analysts expect that IQVIA Holdings Inc. will post 10.12 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.